TB Archives – Page 32 of 49 – Treatment Action Group

Tuberculosis Research Funding Crisis Imperils Elimination Goal

November 30, 2015
Chad Cipiti

Worldwide funding for tuberculosis (TB) research fell $1.3 billion short of global targets in 2014, according to a report released today by Treatment Action Group (TAG). Total funding of US$674,036,492 in 2014 amounted to barely one-third of the US$2 billion experts estimate the world must spend on TB research and development (R&D) each year to eliminate TB. Alarmingly, funding for TB drug research fell by US$25 million compared with 2013. Overall, funding for TB R&D fell by US$12 million.

2015 Report on TB Research Funding Trends

November 25, 2015
Chad Cipiti

Working in tuberculosis (TB) research has long meant laboring with too little and waiting for what comes too late. In recent years, an emergent optimism has crept into TB research, but too often the individuals and institutions that comprise the TB research field find their good ideas and energy put on hold by insufficient funding.

The FDA’s Concession Conundrum

October 6, 2015
Chad Cipiti

Can regulatory incentives promote responsible TB drug development? By Lindsay McKenna and Erica Lessem There are woefully few drugs in development with the potential to improve the safety and effectiveness of tuberculosis (TB) treatment. Indeed, the market-driven approach to drug…

Improving Regulatory Systems to Address Global TB Drug Access Failures

October 6, 2015
Chad Cipiti

Worldwide inefficiencies in drug approval processes are proving disastrous for people living with TB and other diseases By Erica Lessem Access to safe and effective tuberculosis (TB) medicines depends greatly on efficient and stringent regulatory review, without which improved health…

TAGline Fall 2015

October 6, 2015
Chad Cipiti

In Defense of Stringency: In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.

2015 Pipeline Report

July 17, 2015
Chad Cipiti

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

TB R&D’s Shift to the Left

April 8, 2015
Chad Cipiti

As the Bill & Melinda Gates Foundation realigns its TB vaccine strategy to focus on early-stage candidate development, equitable access priorities must also be established before large-scale trials are conducted By Mike Frick The Bill & Melinda Gates Foundation has…

On Targets and Timelines

April 8, 2015
Chad Cipiti

By Tim Horn With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization…

TAGline Spring 2015

April 8, 2015
Chad Cipiti

On Targets and Timelines: With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.

Letter Calling on The Union to Retire Stigmatizing and Criminalizing Language

March 10, 2015
Dorrit Walsh

TAG, CRAG, and other civil society organizations sent this letter to The Union, asking them, as producers of the world’s largest TB conference and publisher of the field’s flagship journal to lead by example...